Barclays PLC Arbutus Biopharma Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Barclays PLC holds 272,029 shares of ABUS stock, worth $865,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares

272,029

Previous 272,029 -0.0%

Holding current value

$865,052

Previous $1.05 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.12 - $4.56 $698,864 - $1.02 Million	223,995 Added 466.33%	272,029 $1.05 Million
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $103,703 - $149,381	-41,152 Reduced 46.14%	48,034 $148,000
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $286,470 - $370,130	-126,757 Reduced 58.7%	89,186 $230,000
Q4 2023 Feb 15, 2024	BUY	$1.69 - $2.54 $142,125 - $213,608	84,098 Added 63.79%	215,943 $540,000
Q3 2023 Nov 07, 2023	BUY	$1.9 - $2.27 $159,505 - $190,566	83,950 Added 175.28%	131,845 $268,000
Q2 2023 Aug 03, 2023	SELL	$2.24 - $3.06 $21,645 - $29,568	-9,663 Reduced 16.79%	47,895 $110,000
Q1 2023 May 04, 2023	BUY	$2.23 - $3.1 $60,330 - $83,867	27,054 Added 88.69%	57,558 $175,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $49,516 - $73,886	25,925 Added 566.17%	30,504 $71,000
Q3 2022 Nov 03, 2022	SELL	$1.88 - $2.88 $1,581 - $2,422	-841 Reduced 15.52%	4,579 $9,000
Q2 2022 Aug 12, 2022	SELL	$1.98 - $3.17 $652,164 - $1.04 Million	-329,376 Reduced 98.38%	5,420 $15,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $153,287 - $252,101	63,342 Added 23.33%	334,796 $997,000
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $1.13 Million - $1.68 Million	-364,002 Reduced 57.28%	271,454 $1.06 Million
Q3 2021 Nov 09, 2021	BUY	$2.65 - $4.62 $1.66 Million - $2.89 Million	625,543 Added 6310.33%	635,456 $2.73 Million
Q2 2021 Aug 13, 2021	SELL	$2.5 - $3.51 $232,390 - $326,275	-92,956 Reduced 90.36%	9,913 $30,000
Q1 2021 May 13, 2021	BUY	$3.14 - $4.84 $321,780 - $495,993	102,478 Added 26209.21%	102,869 $342,000
Q4 2020 Feb 11, 2021	BUY	$2.76 - $4.97 $1,079 - $1,943	391 New	391 $1,000
Q1 2020 May 13, 2020	SELL	$1.01 - $3.42 $363 - $1,231	-360 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$0.87 - $2.89 $629 - $2,089	-723 Reduced 66.76%	360 $1,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $98,041 - $175,596	-73,165 Reduced 98.54%	1,083 $2,000
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $86,290 - $262,417	59,103 Added 390.25%	74,248 $155,000
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $8,797 - $11,790	2,580 Added 20.53%	15,145 $54,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $4,214 - $11,630	-1,204 Reduced 8.74%	12,565 $48,000
Q3 2018 Nov 14, 2018	BUY	$7.85 - $12.35 $87,739 - $138,035	11,177 Added 431.21%	13,769 $130,000
Q2 2018 Aug 14, 2018	BUY	$5.0 - $7.35 $12,300 - $18,081	2,460 Added 1863.64%	2,592 $19,000
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $319,743 - $439,647	-72,669 Reduced 99.82%	132 $1,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $13,083 - $22,638	-2,940 Reduced 3.88%	72,801 $368,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $257,519 - $530,187	75,741	75,741 $470,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $477M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account